Health Care • Biotechnology: Pharmaceutical Preparations
$3.90 ▲ +0.25
(+6.85%)
MKT CAP: $244.7M • VOL: 152.0K
52W L $3 52W H $8
CAMP // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $3.5M | $652.0K | $350.0K |
| YoY Revenue Growth % | +436.5% | +86.3% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$52.6M | -$53.1M | -$51.9M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$80.4M | -$51.8M | -$49.3M |
| EBITDA (Normalized) | -$52.3M | -$52.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$29.6M | -$45.6M | -$44.2M |
| Capital Expenditures (CapEx) | $279.0K | $441.0K | — |
| Free Cash Flow (FCF) | -$29.8M | -$46.0M | -$44.2M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $109.5M | $64.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $47.7M | $63.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CAMP.